References
- Deeks SG. HIV: shock and kill. Nature. 2012;487:439–440.
- Rasmussen TA, Tolstrup M, Søgaard OS. Reversal of latency as part of a cure for HIV-1. Trends Microbiol. 2016;24(2):90–97.
- Jones RB, Walker BD. HIV-specific CD8+ T cells and HIV eradication. J Clin Invest. 2016;126(2):455–463.
- Richman DD, Margolis DM, Delaney M, et al. The challenge of finding a cure for HIV infection. Science. 2009;323:1304–1307.
- Rasmussen TA, Tolstrup M, Winckelmann A, et al. Eliminating the latent HIV reservoir by reactivation strategies: advancing to clinical trials. Hum Vaccin Immunother. 2013;9:790–799.
- Katlama C, Deeks SG, Autran B, et al. Barriers to a cure for HIV: new ways to target and eradicate HIV-1 reservoirs. Lancet. 2013;381:2109–2117.
- Wightman F, Ellenberg P, Churchill M, et al. HDAC inhibitors in HIV. Immunol Cell Biol. 2012;90:47–54.
- Barton KM, Archin NM, Keedy KS, et al. Selective HDAC inhibition for the disruption of latent HIV-1 infection. PLoS One. 2014;9:e102684.
- Bertino EM, Otterson GA. Romidepsin: a novel histone deacetylase inhibitor for cancer. Expert Opin Investig Drugs. 2011;20:1151–1158.
- Wei DG, Chiang V, Fyne E, et al. Histone deacetylase inhibitor romidepsin induces hiv expression in cd4 t cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog. 2014;10:e1004071.
- Søgaard OS, Graversen ME, Leth S, et al. The depsipeptide romidepsin reverses HIV-1 latency in vivo. PLOS Pathog. 2015;11:e1005142.
- Jones RB, O’Connor R, Mueller S, et al. Histone deacetylase inhibitors impair the elimination of HIV-infected cells by Cytotoxic T-lymphocytes. PLoS Pathog. 2014;10:e1004287.
- Del Prete GQ, Oswald K, Lara A, et al. Elevated plasma viral loads in romidepsin treated SIV-infected rhesus macaques on suppressive combination antiretroviral therapy. Antimicrob Agents Chemother. 2015;60(3):1560–1572.
- Archin NM, Liberty AL, Kashuba AD, et al. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Nature. 2012;487:482–485.
- Archin NM, Bateson R, Tripathy MK, et al. HIV-1 expression within resting CD4 T-cells following multiple doses of vorinostat. J Infect Dis. 2014;11:1–8.
- Rasmussen TA, Tolstrup M, Brinkmann CR, et al. Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial. Lancet HIV. 2014;3018:1–9.
- Olesen R, Vigano S, Rasmussen TA, et al. Innate immune activity correlates with CD4 T cell-associated HIV-1 DNA decline during latency-reversing treatment with panobinostat. J Virol. 2015;89:10176–10189.
- Jain S, Zain J. Romidepsin in the treatment of cutaneous T-cell lymphoma. J Blood Med. 2011;2:37–47.
- Hurst T, Pace M, Katzourakis A, et al. Human endogenous retrovirus (HERV) expression is not induced by treatment with the histone deacetylase (HDAC) inhibitors in cellular models of HIV-1 latency. Retrovirology. 2016;13:10.
- Laird GM, Bullen CK, Rosenbloom DIS, et al. Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest. 2015;125:1901–1912.
- Shan L, Deng K, Shroff NS, et al. Stimulation of HIV-1-specific Cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity. 2012;36:491–501.
- Ananworanich J, Dubé K, Chomont N. How does the timing of antiretroviral therapy initiation in acute infection affect HIV reservoirs? Curr Opin HIV AIDS. 2015;10:18–28.
- Deng K, Pertea M, Rongvaux A, et al. Broad CTL response is required to clear latent HIV-1 due to dominance of escape mutations. Nature. 2015;517:381–385.
- Kent SJ, Reece JC, Petravic J, et al. The search for an HIV cure: tackling latent infection. Lancet Infect Dis. 2013;13:614–621.
- Reece JC, Martyushev A, Petravic J, et al. Measuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapies. PLoS One. 2014;9:e93330.
- Petravic J, Martyushev A, Reece JC, et al. Modeling the timing of antilatency drug administration during HIV treatment. J Virol. 2014;88:14050–14056.
- Jønsson KL, Tolstrup M, Vad-Nielsen J, et al. Histone deacetylase inhibitor romidepsin inhibits De Novo HIV-1 infections. Antimicrob Agents Chemother. 2015;59:3984–3994.
- Berg SL, Stone J, Xiao JJ, et al. Plasma and cerebrospinal fluid pharmacokinetics of depsipeptide (FR901228) in nonhuman primates. Cancer Chemother Pharmacol. 2004;54:85–88.
- Leth S, Nymann R, Jørgensen S, et al. HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on ART. Aids. 2016;30(5):713–721.